Optimization of a urea-containing series of nicotinamide phosphoribosyltransferase (NAMPT) activators
作者:Anthony B. Pinkerton、E. Hampton Sessions、Paul Hershberger、Patrick R. Maloney、Satyamaheshwar Peddibhotla、Meghan Hopf、Eduard Sergienko、Chen-Ting Ma、Layton H. Smith、Michael R. Jackson、Jun Tanaka、Takashi Tsuji、Mayuko Akiu、Steven E. Cohen、Tsuyoshi Nakamura、Stephen J. Gardell
DOI:10.1016/j.bmcl.2021.128007
日期:2021.6
neurodegeneration, and muscle wasting disorders. A novel strategy to boost NAD+ is to activate nicotinamide phosphoribosyltransferase (NAMPT), the putative rate-limiting step in the NAD+ salvage pathway. We previously showed that NAMPT activators increase NAD+ levels in vitro and in vivo. Herein we describe the optimization of our NAMPT activator prototype (SBI-0797812) leading to the identification of 1-(4-((4-ch
NAD +是一种关键的细胞因子,在广泛的生物过程中发挥着多方面的作用。低水平的 NAD +与许多疾病有关,包括代谢紊乱、心血管疾病、神经变性和肌肉萎缩症。一种提高 NAD + 的新策略是激活烟酰胺磷酸核糖基转移酶 (NAMPT),这是 NAD +补救途径中推定的限速步骤。我们之前表明 NAMPT 激活剂可在体外和体内增加 NAD +水平. 在此,我们描述了我们的 NAMPT 活化剂原型 (SBI-0797812) 的优化,导致 1-(4-((4-氯苯基)磺酰基)苯基)-3-(恶唑-5-基甲基)脲 ( 34 )的鉴定显示出更有效的 NAMPT 激活和改善的口服生物利用度。